Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286295086> ?p ?o ?g. }
- W4286295086 endingPage "8020" @default.
- W4286295086 startingPage "8020" @default.
- W4286295086 abstract "8020 Background: Cohort A of the multicohort phase 2 CARTITUDE-2 (NCT04133636) study is evaluating cilta-cel safety and efficacy in pts with MM who received 1–3 prior LOT and were len-refractory – a difficult-to-treat population with poor prognosis. We present updated results. Methods: Pts had progressive MM after 1–3 prior LOT, including a PI and IMiD, were len-refractory, and had no prior exposure to BCMA-targeting agents. A single cilta-cel infusion (target dose 0.75×10 6 CAR+ viable T cells/kg) was given post lymphodepletion. Safety and efficacy were assessed, and the primary endpoint was MRD negativity at 10 -5 . Management strategies were implemented to minimize risk of movement/neurocognitive AEs (MNTs). Pharmacokinetic (PK) analyses (C max and T max of CAR+ T-cell transgene levels in blood) are being conducted, as well as analyses of levels of CRS-related cytokines (eg, IL-6) over time, peak levels of cytokines by response and CRS, association of cytokine levels with ICANS, and CAR+ T cell CD4/CD8 ratio by response, CRS, and ICANS. Results: As of January 2022 (median follow-up [MFU] 17.1 mo [range 3.3–23.1]), 20 pts (65% male; median age 60 y [range 38–75]) received cilta-cel. Pts received a median of 2 (range 1–3) prior LOT, and a median of 3.5 y (range 0.7–8.0) since MM diagnosis. 95% were refractory to last LOT, and 40% were triple-class refractory. ORR was 95%, 90% achieved CR or better, and 95% had ≥VGPR. Median times to first and best response were 1.0 mo (range 0.7–3.3) and 2.6 mo (range 0.9–13.6), respectively. 16 pts were MRD-evaluable, all of whom achieved MRD negativity at 10 -5 . Median DOR was not reached and 12-mo event-free rate was 79%. The 12-mo PFS rate was 75%. Median time to onset of CRS was 7 d (range 5–9) and occurred in 95% of pts (gr 3/4: 10%), with median duration of 3 d (range 2–12). Neurotoxicity occurred in 30% of pts (5 gr 1/2; 1 gr 3/4). 3 pts (15%) had ICANS (all gr 1/2); 1 pt had gr 2 facial paralysis. No MNTs were seen. 1 death occurred due to COVID-19 (assessed as tx-related by the investigator), 2 due to progressive disease, and 1 due to sepsis (not related to tx). Preliminary PK analyses indicate that peak expansion of CAR-T cells occurred at d 10.5 (range 8.7–42.9) and median persistence was 153.5 d (range 57.1–336.8). Conclusions: At a longer MFU of 17.1 mo, a single cilta-cel infusion led to deepening and durable responses in pts with MM who had 1–3 prior LOT and were len-refractory. Follow-up is ongoing. Updated and in-depth PK, cytokine, and CAR-T subset analyses and clinical correlation will be presented and provide novel insights into biological correlates of efficacy and safety in this pt population. This pt population is being further evaluated in the CARTITUDE-4 study (NCT04181827), which has concluded enrollment. Clinical trial information: NCT04133636." @default.
- W4286295086 created "2022-07-21" @default.
- W4286295086 creator A5003185875 @default.
- W4286295086 creator A5006799794 @default.
- W4286295086 creator A5007194262 @default.
- W4286295086 creator A5008309494 @default.
- W4286295086 creator A5013012503 @default.
- W4286295086 creator A5016360607 @default.
- W4286295086 creator A5019564821 @default.
- W4286295086 creator A5022228597 @default.
- W4286295086 creator A5022231850 @default.
- W4286295086 creator A5022522496 @default.
- W4286295086 creator A5025168585 @default.
- W4286295086 creator A5035223625 @default.
- W4286295086 creator A5040950497 @default.
- W4286295086 creator A5047272364 @default.
- W4286295086 creator A5049071496 @default.
- W4286295086 creator A5068472643 @default.
- W4286295086 creator A5078767512 @default.
- W4286295086 creator A5079645349 @default.
- W4286295086 creator A5086077649 @default.
- W4286295086 creator A5088893374 @default.
- W4286295086 date "2022-06-01" @default.
- W4286295086 modified "2023-10-16" @default.
- W4286295086 title "Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A." @default.
- W4286295086 doi "https://doi.org/10.1200/jco.2022.40.16_suppl.8020" @default.
- W4286295086 hasPublicationYear "2022" @default.
- W4286295086 type Work @default.
- W4286295086 citedByCount "2" @default.
- W4286295086 countsByYear W42862950862023 @default.
- W4286295086 crossrefType "journal-article" @default.
- W4286295086 hasAuthorship W4286295086A5003185875 @default.
- W4286295086 hasAuthorship W4286295086A5006799794 @default.
- W4286295086 hasAuthorship W4286295086A5007194262 @default.
- W4286295086 hasAuthorship W4286295086A5008309494 @default.
- W4286295086 hasAuthorship W4286295086A5013012503 @default.
- W4286295086 hasAuthorship W4286295086A5016360607 @default.
- W4286295086 hasAuthorship W4286295086A5019564821 @default.
- W4286295086 hasAuthorship W4286295086A5022228597 @default.
- W4286295086 hasAuthorship W4286295086A5022231850 @default.
- W4286295086 hasAuthorship W4286295086A5022522496 @default.
- W4286295086 hasAuthorship W4286295086A5025168585 @default.
- W4286295086 hasAuthorship W4286295086A5035223625 @default.
- W4286295086 hasAuthorship W4286295086A5040950497 @default.
- W4286295086 hasAuthorship W4286295086A5047272364 @default.
- W4286295086 hasAuthorship W4286295086A5049071496 @default.
- W4286295086 hasAuthorship W4286295086A5068472643 @default.
- W4286295086 hasAuthorship W4286295086A5078767512 @default.
- W4286295086 hasAuthorship W4286295086A5079645349 @default.
- W4286295086 hasAuthorship W4286295086A5086077649 @default.
- W4286295086 hasAuthorship W4286295086A5088893374 @default.
- W4286295086 hasConcept C121332964 @default.
- W4286295086 hasConcept C121608353 @default.
- W4286295086 hasConcept C126322002 @default.
- W4286295086 hasConcept C141071460 @default.
- W4286295086 hasConcept C142424586 @default.
- W4286295086 hasConcept C143998085 @default.
- W4286295086 hasConcept C2776063141 @default.
- W4286295086 hasConcept C2776364478 @default.
- W4286295086 hasConcept C2777701055 @default.
- W4286295086 hasConcept C2780850621 @default.
- W4286295086 hasConcept C2908647359 @default.
- W4286295086 hasConcept C3875195 @default.
- W4286295086 hasConcept C71924100 @default.
- W4286295086 hasConcept C72563966 @default.
- W4286295086 hasConcept C87355193 @default.
- W4286295086 hasConcept C90924648 @default.
- W4286295086 hasConcept C99454951 @default.
- W4286295086 hasConceptScore W4286295086C121332964 @default.
- W4286295086 hasConceptScore W4286295086C121608353 @default.
- W4286295086 hasConceptScore W4286295086C126322002 @default.
- W4286295086 hasConceptScore W4286295086C141071460 @default.
- W4286295086 hasConceptScore W4286295086C142424586 @default.
- W4286295086 hasConceptScore W4286295086C143998085 @default.
- W4286295086 hasConceptScore W4286295086C2776063141 @default.
- W4286295086 hasConceptScore W4286295086C2776364478 @default.
- W4286295086 hasConceptScore W4286295086C2777701055 @default.
- W4286295086 hasConceptScore W4286295086C2780850621 @default.
- W4286295086 hasConceptScore W4286295086C2908647359 @default.
- W4286295086 hasConceptScore W4286295086C3875195 @default.
- W4286295086 hasConceptScore W4286295086C71924100 @default.
- W4286295086 hasConceptScore W4286295086C72563966 @default.
- W4286295086 hasConceptScore W4286295086C87355193 @default.
- W4286295086 hasConceptScore W4286295086C90924648 @default.
- W4286295086 hasConceptScore W4286295086C99454951 @default.
- W4286295086 hasFunder F4320337415 @default.
- W4286295086 hasIssue "16_suppl" @default.
- W4286295086 hasLocation W42862950861 @default.
- W4286295086 hasOpenAccess W4286295086 @default.
- W4286295086 hasPrimaryLocation W42862950861 @default.
- W4286295086 hasRelatedWork W1988934582 @default.
- W4286295086 hasRelatedWork W2017335120 @default.
- W4286295086 hasRelatedWork W2102372291 @default.
- W4286295086 hasRelatedWork W2111732928 @default.
- W4286295086 hasRelatedWork W2129596076 @default.
- W4286295086 hasRelatedWork W2351796763 @default.
- W4286295086 hasRelatedWork W2531713994 @default.
- W4286295086 hasRelatedWork W2899586773 @default.